

# **Translation of Amended Claims under PCT Article 19**

PCT/EP2004/004776

March 2, 2005

45 818 K

New patent claims:

1. The use of an inhibitor of the t-PA-mediated  
activation of the glutamate receptor, preferably  
5 of the NMDA type, for the treatment of depression  
or anxiety states in humans.
2. The use as claimed in any of the preceding claims,  
characterized by employment of a protease which  
10 inhibits t-PA activity.
3. The use as claimed in claim 2, characterized by a  
serine protease inhibitor, preferably neuroserpin,  
plasminogen activator inhibitor (PAI) or protease  
15 nexin I (PN-1).
4. The use as claimed in any of claims 1 to 3,  
characterized by the use of DSPA or derivatives,  
analogues or fragments which can be functionally  
20 and/or structurally derived therefrom.
5. The use as claimed in claim 4, characterized in  
that DSPA having an amino acid sequence as shown  
in fig. 1 or DSPA derivatives, analogues or  
25 fragments having at least 70%, preferably 80 to  
90%, homology thereto are used.
6. The use as claimed in claim 4 or 5, characterized  
by a dosage of greater than 62.5 and less than  
30 160 microg/kg DSPA as shown in fig. 1, preferably  
from 90 to 125 microg/kg DSPA, particularly  
preferably 90 microg/kg DSPA, or of a dosage  
adjusted thereto depending on the bioequivalence  
of the derivative, analogue or fragment used.  
35
7. The use as claimed in any of claims 4 to 6,  
characterized in that DSPA or derivatives, analogues  
or fragments thereof is employed as

neuroprotective in the treatment of stroke in combination with a thrombolytic.

- 5       8.    The use as claimed in claim 7, characterized by t-PA as thrombolytic.
- 10       9.    The use of DSPA or derivatives, analogs or fragments which can be functionally and/or structurally derived therefrom as neuroprotective in humans.
- 15       10.   The use as claimed in claim 9 for the treatment of depression or anxiety states.
- 20       11.   The use as claimed in claim 9, characterized by the treatment or prophylaxis of one of the following conditions: Parkinsonism, Alzheimer's, Huntington's chorea, diabetes, painful conditions, epilepsy or memory disturbances.